Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1474

1.

O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.

Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Kauffman EPS, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG.

Cancer Cell. 2017 Aug 14;32(2):268. doi: 10.1016/j.ccell.2017.07.008. No abstract available.

PMID:
28810149
2.

Implementing a Disaster Preparedness Curriculum for Medical Students.

Jasper EH, Wanner GK, Berg D, Berg K.

South Med J. 2017 Aug;110(8):523-527. doi: 10.14423/SMJ.0000000000000681.

PMID:
28771649
3.

Correction: Human mutations in integrator complex subunits link transcriptome integrity to brain development.

Oegema R, Baillat D, Schot R, van Unen LM, Brooks A, Kia SK, Hoogeboom AJM, Xia Z, Li W, Cesaroni M, Lequin MH, van Slegtenhorst M, Dobyns WB, de Coo IFM, van den Berg D, Verheijen FW, Kremer A, van der Spek PJ, Heijsman D, Wagner EJ, Fornerod M, Mancini GMS.

PLoS Genet. 2017 Aug 1;13(8):e1006923. doi: 10.1371/journal.pgen.1006923. eCollection 2017 Aug.

4.

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1.

Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM, Gimsing P, Hamadani M, Borsaru G, Berg D, Lin J, Di Bacco A, van de Velde H, Richardson PG, Moreau P.

Haematologica. 2017 Jul 27. pii: haematol.2017.170118. doi: 10.3324/haematol.2017.170118. [Epub ahead of print]

5.

Patient Handoff Education: Are Medical Schools Catching Up?

Davis R, Davis J, Berg K, Berg D, Morgan CJ, Russo S, Riesenberg LA.

Am J Med Qual. 2017 Jul 1:1062860617719128. doi: 10.1177/1062860617719128. [Epub ahead of print]

PMID:
28728430
6.

Using community-based participatory research and organizational diagnosis to characterize relationships between community leaders and academic researchers.

Wang KH, Ray NJ, Berg DN, Greene AT, Lucas G, Harris K, Carroll-Scott A, Tinney B, Rosenthal MS.

Prev Med Rep. 2017 Jun 21;7:180-186. doi: 10.1016/j.pmedr.2017.06.007. eCollection 2017 Sep.

7.

Multiresponsive Nanogels for Targeted Anticancer Drug Delivery.

Zhang Q, Colazo J, Berg D, Mugo SM, Serpe MJ.

Mol Pharm. 2017 Aug 7;14(8):2624-2628. doi: 10.1021/acs.molpharmaceut.7b00325. Epub 2017 Jul 7.

PMID:
28686454
8.

Progression markers of motor deficits in Parkinson's disease: A biannual 4-year prospective study.

Heinzel S, Bernhard FP, Roeben B, Nussbaum S, Heger T, Martus P, Hobert MA, Maetzler W, Berg D.

Mov Disord. 2017 Jul 6. doi: 10.1002/mds.27062. [Epub ahead of print] No abstract available.

PMID:
28681985
9.

Dopaminergic Therapies for Non-motor Symptoms in Parkinson's Disease.

Schaeffer E, Berg D.

CNS Drugs. 2017 Jul;31(7):551-570. doi: 10.1007/s40263-017-0450-z. Review.

PMID:
28643183
10.

Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.

Lee AJ, Wang Y, Alcalay RN, Mejia-Santana H, Saunders-Pullman R, Bressman S, Corvol JC, Brice A, Lesage S, Mangone G, Tolosa E, Pont-Sunyer C, Vilas D, Schüle B, Kausar F, Foroud T, Berg D, Brockmann K, Goldwurm S, Siri C, Asselta R, Ruiz-Martinez J, Mondragón E, Marras C, Ghate T, Giladi N, Mirelman A, Marder K; Michael J. Fox LRRK2 Cohort Consortium.

Mov Disord. 2017 Jun 22. doi: 10.1002/mds.27059. [Epub ahead of print]

PMID:
28639421
11.

Gait Is Associated with Cognitive Flexibility: A Dual-Tasking Study in Healthy Older People.

Hobert MA, Meyer SI, Hasmann SE, Metzger FG, Suenkel U, Eschweiler GW, Berg D, Maetzler W.

Front Aging Neurosci. 2017 May 24;9:154. doi: 10.3389/fnagi.2017.00154. eCollection 2017.

12.

Global, Yet Incomplete Overview of Cohort Studies in Parkinson's disease.

Heinzel S, Lerche S, Maetzler W, Berg D.

J Parkinsons Dis. 2017;7(3):423-432. doi: 10.3233/JPD-171100.

PMID:
28582871
13.

Diurnal variation in the pharmacokinetics and brain distribution of morphine and its major metabolite.

Kervezee L, Hartman R, van den Berg DJ, Meijer JH, de Lange ECM.

Eur J Pharm Sci. 2017 May 27. pii: S0928-0987(17)30277-4. doi: 10.1016/j.ejps.2017.05.048. [Epub ahead of print]

PMID:
28558980
14.

The New Diagnostic Criteria for Parkinson's Disease.

Postuma RB, Berg D.

Int Rev Neurobiol. 2017;132:55-78. doi: 10.1016/bs.irn.2017.01.008. Epub 2017 Mar 3.

PMID:
28554421
15.

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.

Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G.

Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26.

PMID:
28550039
16.

Gene expression analysis of bovine embryonic disc, trophoblast and parietal hypoblast at the start of gastrulation.

Pfeffer PL, Smith CS, Maclean P, Berg DK.

Zygote. 2017 Jun;25(3):265-278. doi: 10.1017/S0967199417000090. Epub 2017 May 23.

PMID:
28534463
17.

Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts.

Pilotto A, Heinzel S, Suenkel U, Lerche S, Brockmann K, Roeben B, Schaeffer E, Wurster I, Yilmaz R, Liepelt-Scarfone I, von Thaler AK, Metzger FG, Eschweiler GW, Postuma RB, Maetzler W, Berg D.

Mov Disord. 2017 Jul;32(7):1025-1034. doi: 10.1002/mds.27035. Epub 2017 May 16.

PMID:
28509336
18.

Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia.

Berg DD, Vaduganathan M, Nohria A, Davids MS, Alyea EP, Torre M, Padera RF Jr.

Eur J Heart Fail. 2017 May;19(5):682-685. doi: 10.1002/ejhf.806. No abstract available.

PMID:
28485549
19.

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, Spencer A, Hájek R, Romeril K, Avivi I, Liberati AM, Minnema MC, Einsele H, Lonial S, Berg D, Lin J, Gupta N, Esseltine DL, Richardson PG.

Br J Haematol. 2017 Aug;178(4):571-582. doi: 10.1111/bjh.14733. Epub 2017 May 9.

PMID:
28485007
20.

A Cre Mouse Line for Probing Irradiance- and Direction-Encoding Retinal Networks.

Sabbah S, Berg D, Papendorp C, Briggman KL, Berson DM.

eNeuro. 2017 May 1;4(2). pii: ENEURO.0065-17.2017. doi: 10.1523/ENEURO.0065-17.2017. eCollection 2017 Mar-Apr.

Supplemental Content

Support Center